mp.weixin.qq.com·· 11 hours agoPickScore96
Phase III SANOVO Shows Osimertinib Plus Savolitinib Improves PFS and OS as First-Line Treatment in MET-Overexpressed EGFR-Mutated Advanced NSCLC
In brief
The Phase III SANOVO trial showed that first-line osimertinib plus savolitinib in advanced EGFR-mutated NSCLC with MET overexpression reduced the risk of progression or death by 44% versus osimertinib monotherapy in the ITT population, with improvements in both PFS and OS.
Why it matters
SANOVO stratifies by MET expression level and reports PFS, OS and safety, allowing within-trial comparison of combination benefit across populations.
Source: mp.weixin.qq.com · mp.weixin.qq.com